ADP-A2M4

Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential
MedCity News
Tue, 06/2/20 - 10:20 am
Adaptimmune
ASCO 2020
cell therapy
sarcoma
ADP-A2M4
Struggling Adaptimmune gets a boost from the FDA as T-cell cancer drug wins an inside track at the agency
Endpoints
Tue, 12/3/19 - 10:18 am
Adaptimmune
FDA
regenerative medicine
RMAT
ADP-A2M4